NO2842573T3 - - Google Patents
Info
- Publication number
- NO2842573T3 NO2842573T3 NO14188785A NO14188785A NO2842573T3 NO 2842573 T3 NO2842573 T3 NO 2842573T3 NO 14188785 A NO14188785 A NO 14188785A NO 14188785 A NO14188785 A NO 14188785A NO 2842573 T3 NO2842573 T3 NO 2842573T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11268608P | 2008-11-07 | 2008-11-07 | |
| US16487009P | 2009-03-30 | 2009-03-30 | |
| EP09825523.5A EP2365828B1 (en) | 2008-11-07 | 2009-11-06 | Monoclonal antibodies to fibroblast growth factor receptor 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2842573T3 true NO2842573T3 (cg-RX-API-DMAC7.html) | 2018-02-24 |
Family
ID=42153600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14188785A NO2842573T3 (cg-RX-API-DMAC7.html) | 2008-11-07 | 2009-11-06 |
Country Status (20)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| WO2012021841A2 (en) * | 2010-08-12 | 2012-02-16 | Attogen Inc. | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| WO2009100105A2 (en) * | 2008-02-04 | 2009-08-13 | Attogen Inc. | Inhibitors of oncogenic isoforms and uses thereof |
| JP5627591B2 (ja) | 2008-11-07 | 2014-11-19 | ギャラクシー バイオテック， エルエルシー | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| CA2800311A1 (en) * | 2010-05-11 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| JP2015505850A (ja) * | 2011-12-14 | 2015-02-26 | シアトル ジェネティックス， インコーポレイテッド | 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用 |
| DK2822968T3 (en) | 2012-03-08 | 2018-04-16 | Janssen Vaccines & Prevention Bv | HUMAN BINDING MOLECULES ABLE TO BIND AND NEUTRALIZE INFLUENZA-B-VIRA, AND APPLICATIONS THEREOF |
| JP6188681B2 (ja) * | 2012-04-09 | 2017-08-30 | 第一三共株式会社 | 抗ｆｇｆｒ２抗体 |
| WO2014089193A1 (en) * | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| AU2013362937A1 (en) * | 2012-12-21 | 2015-07-02 | Janssen Biotech, Inc. | Sensitive multiplex immunoassay for soluble fibroblast growth factor receptors |
| CN103145843B (zh) * | 2013-02-20 | 2014-10-29 | 暨南大学 | 抗成纤维细胞生长因子受体的单链抗体 |
| MX2015011428A (es) | 2013-03-06 | 2016-02-03 | Genentech Inc | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. |
| NZ715201A (en) * | 2013-08-01 | 2021-12-24 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| JP6509735B2 (ja) * | 2013-10-08 | 2019-05-08 | 第一三共株式会社 | 抗ｆｇｆｒ２抗体と他剤の組合せ |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
| CN104231079A (zh) * | 2014-09-12 | 2014-12-24 | 暨南大学 | 一种靶向bFGF高亲和力受体结合位点的抗体及其应用 |
| TW201642904A (zh) * | 2015-04-08 | 2016-12-16 | 第一三共股份有限公司 | 含抗ｆｇｆｒ２抗體及其他藥劑之組成物 |
| WO2016171107A1 (ja) * | 2015-04-20 | 2016-10-27 | 第一三共株式会社 | Ｆｇｆｒ２の検出 |
| RU2638457C2 (ru) * | 2015-09-28 | 2017-12-13 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител |
| CA3004794A1 (en) * | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
| AU2017233121B2 (en) | 2016-03-15 | 2023-12-21 | Itabmed (Hk) Limited | Multispecific Fab fusion proteins and use thereof |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
| US11603401B2 (en) | 2017-06-02 | 2023-03-14 | Ablynx N.V. | Aggrecan binding immunoglobulins |
| JP7280254B2 (ja) | 2017-10-24 | 2023-05-23 | マジェンタ セラピューティクス インコーポレイテッド | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
| WO2019084067A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | ANTI-CD117 ANTIBODIES AND METHODS OF USE |
| TW201922782A (zh) | 2017-10-24 | 2019-06-16 | 美商麥珍塔治療學股份有限公司 | 去除cd117+細胞之組合物及方法 |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| CN112804989A (zh) | 2018-10-05 | 2021-05-14 | 戊瑞治疗有限公司 | 抗fgfr2抗体制剂 |
| CA3160812A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| CA3160811A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| EP4161566A4 (en) * | 2020-06-03 | 2024-06-12 | The Broad Institute, Inc. | ANTAGONISTIC BIPARATOPIC ANTIBODIES THAT SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USE THEREOF |
| EP4232481A1 (en) | 2020-10-22 | 2023-08-30 | Regeneron Pharmaceuticals, Inc. | Anti-fgfr2 antibodies and methods of use thereof |
| US20240101683A1 (en) * | 2020-12-29 | 2024-03-28 | Shenzhen Forward Pharmaceuticals Co., Limited | Anti-FGFR2 Antibody and Use Thereof |
| EP4414387A4 (en) * | 2021-10-08 | 2025-10-29 | Shenzhen Forward Pharmaceuticals Co Ltd | ANTI-FGFR2 ANTIBODY WITH IMPROVED ADCC AND ITS USE |
| TW202342527A (zh) | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
| KR20250099773A (ko) * | 2022-09-30 | 2025-07-02 | 3에이치 파머슈티컬즈 컴퍼니 리미티드 | 항-fgfr2b 항체 및 이의 용도 |
| TW202442685A (zh) * | 2023-04-28 | 2024-11-01 | 大陸商武漢人福創新藥物研發中心有限公司 | 抗FGFR2b單抗 |
| WO2024240107A1 (zh) * | 2023-05-19 | 2024-11-28 | 广东东阳光药业股份有限公司 | 一种抗fgfr2抗体及其应用 |
| WO2024255756A1 (zh) * | 2023-06-13 | 2024-12-19 | 南京维立志博生物科技股份有限公司 | 基于共同轻链产生双特异性抗体的方法 |
| TW202527998A (zh) * | 2023-12-18 | 2025-07-16 | 大陸商山東先聲生物製藥有限公司 | 抗FGFR2b抗體-藥物綴合物及其應用 |
| WO2025218662A1 (zh) * | 2024-04-16 | 2025-10-23 | 杭州中美华东制药有限公司 | 抗成纤维细胞生长因子受体2b的抗体及其用途 |
| WO2025232811A1 (zh) * | 2024-05-09 | 2025-11-13 | 正大天晴药业集团股份有限公司 | 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU638734B2 (en) | 1989-07-06 | 1993-07-08 | Regents Of The University Of California, The | Receptors for fibroblast growth factors |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5620889A (en) * | 1993-10-14 | 1997-04-15 | Immunex Corporation | Human anti-Fas IgG1 monoclonal antibodies |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6323316B1 (en) | 1996-06-18 | 2001-11-27 | The United States Of America As Represented By The Secretary Of The Department Of And Human Services | Fibroblast growth factor receptor activating gene 1 and related compositions and methods |
| US20030143676A1 (en) * | 1999-03-25 | 2003-07-31 | Genesis Research And Development Corporation Limited | Fibroblast growth factor receptors and methods for their use |
| WO2000064946A2 (en) * | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| JP2001302699A (ja) | 2000-04-17 | 2001-10-31 | Nichirei Corp | ヒトｋｇｆｒに対する抗体 |
| US20020115603A1 (en) | 2000-06-22 | 2002-08-22 | Chiron Corporation | Methods and compositions for the treatment of peripheral artery disease |
| KR100945108B1 (ko) * | 2001-06-13 | 2010-03-02 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체 |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| WO2003063893A2 (en) | 2002-01-31 | 2003-08-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Fgfr agonists |
| KR100493460B1 (ko) * | 2002-08-29 | 2005-06-07 | 재단법인서울대학교산학협력재단 | 암 세포에서 발현되는 ｆｇｆｒ2 이성체 |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| EP2341067A1 (en) | 2003-07-18 | 2011-07-06 | Amgen, Inc | Specific binding agents to hepatocyte growth factor |
| US20070248605A1 (en) * | 2003-12-19 | 2007-10-25 | Five Prime Therapetutics, Inc. | Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention |
| WO2005115363A2 (en) | 2004-05-25 | 2005-12-08 | Yale University | Method for treating skeletal disorders resulting from fgfr malfunction |
| WO2007114896A2 (en) | 2006-03-31 | 2007-10-11 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
| AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| WO2007134210A2 (en) * | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
| NZ573818A (en) | 2006-06-02 | 2011-09-30 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins |
| NZ573819A (en) | 2006-06-02 | 2011-09-30 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins |
| CA2655504A1 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| ME02371B (me) | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| EP2094733A1 (en) * | 2006-11-03 | 2009-09-02 | U3 Pharma GmbH | Fgfr4 antibodies |
| ES2600882T3 (es) * | 2007-03-23 | 2017-02-13 | The Translational Genomics Research Institute | Procedimiento de clasificación del cáncer de endometrio |
| US20110091473A1 (en) | 2007-10-22 | 2011-04-21 | Genmab A/S | Novel antibody therapies |
| WO2009100105A2 (en) | 2008-02-04 | 2009-08-13 | Attogen Inc. | Inhibitors of oncogenic isoforms and uses thereof |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| JP5627591B2 (ja) | 2008-11-07 | 2014-11-19 | ギャラクシー バイオテック， エルエルシー | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| US20120301482A1 (en) | 2009-08-25 | 2012-11-29 | National Jewish Health | Methods and compositions for treatment of lung injury |
-
2009
- 2009-11-06 JP JP2011534932A patent/JP5627591B2/ja active Active
- 2009-11-06 ES ES14188785.1T patent/ES2646168T3/es active Active
- 2009-11-06 PT PT171911183T patent/PT3290052T/pt unknown
- 2009-11-06 PT PT141887851T patent/PT2842573T/pt unknown
- 2009-11-06 ES ES17191118T patent/ES2770134T3/es active Active
- 2009-11-06 EP EP09825523.5A patent/EP2365828B1/en active Active
- 2009-11-06 DK DK09825523.5T patent/DK2365828T3/en active
- 2009-11-06 PL PL14188785T patent/PL2842573T3/pl unknown
- 2009-11-06 BR BRPI0917315A patent/BRPI0917315B8/pt active IP Right Grant
- 2009-11-06 ES ES09825523.5T patent/ES2523740T3/es active Active
- 2009-11-06 DK DK14188785.1T patent/DK2842573T3/en active
- 2009-11-06 NO NO14188785A patent/NO2842573T3/no unknown
- 2009-11-06 WO PCT/US2009/063647 patent/WO2010054265A2/en not_active Ceased
- 2009-11-06 LT LTEP17191118.3T patent/LT3290052T/lt unknown
- 2009-11-06 SI SI200932035T patent/SI3290052T1/sl unknown
- 2009-11-06 EP EP19193727.5A patent/EP3783024A1/en active Pending
- 2009-11-06 PL PL09825523T patent/PL2365828T3/pl unknown
- 2009-11-06 HU HUE14188785A patent/HUE035700T2/en unknown
- 2009-11-06 EP EP14188785.1A patent/EP2842573B1/en active Active
- 2009-11-06 CA CA2733668A patent/CA2733668C/en active Active
- 2009-11-06 US US12/614,282 patent/US8101723B2/en active Active
- 2009-11-06 KR KR1020117002577A patent/KR101699432B1/ko active Active
- 2009-11-06 EP EP17191118.3A patent/EP3290052B1/en active Active
- 2009-11-06 CA CA3166399A patent/CA3166399A1/en active Pending
- 2009-11-06 PT PT98255235T patent/PT2365828E/pt unknown
- 2009-11-06 SI SI200931763T patent/SI2842573T1/en unknown
- 2009-11-06 DK DK17191118.3T patent/DK3290052T3/da active
- 2009-11-06 AU AU2009313357A patent/AU2009313357B2/en active Active
- 2009-11-06 LT LTEP14188785.1T patent/LT2842573T/lt unknown
- 2009-11-06 MX MX2011000455A patent/MX2011000455A/es active IP Right Grant
- 2009-11-06 PL PL17191118T patent/PL3290052T3/pl unknown
- 2009-11-06 RU RU2011141890/10A patent/RU2546254C9/ru active
- 2009-11-06 CN CN200980132269.2A patent/CN102131524B/zh active Active
-
2011
- 2011-10-28 US US13/284,838 patent/US8603987B2/en active Active
-
2013
- 2013-11-04 US US14/071,520 patent/US9382324B2/en active Active
-
2014
- 2014-06-04 JP JP2014115617A patent/JP6342223B2/ja active Active
-
2016
- 2016-06-02 US US15/172,033 patent/US9834609B2/en active Active
- 2016-08-03 JP JP2016152670A patent/JP6445496B2/ja active Active
-
2017
- 2017-08-10 US US15/674,385 patent/US10138301B2/en active Active
- 2017-10-26 HR HRP20171640TT patent/HRP20171640T1/hr unknown
-
2018
- 2018-10-18 US US16/164,530 patent/US10689448B2/en active Active
- 2018-11-29 JP JP2018223183A patent/JP6661734B2/ja active Active
-
2020
- 2020-01-20 HR HRP20200090TT patent/HRP20200090T1/hr unknown
- 2020-02-06 JP JP2020018719A patent/JP6960485B2/ja active Active
- 2020-05-05 US US16/867,398 patent/US20200347141A1/en not_active Abandoned
-
2021
- 2021-10-11 JP JP2021166672A patent/JP7301106B2/ja active Active
-
2023
- 2023-03-10 US US18/182,242 patent/US20230242650A1/en active Pending
- 2023-06-20 JP JP2023100475A patent/JP2023116746A/ja active Pending
-
2024
- 2024-11-05 JP JP2024193584A patent/JP2025032085A/ja active Pending